Evidence map›Paper›PMID 40114953›Full record

ArticleTranslational lung cancer research2025

Novel

Wai Park, Jeremy Fricke, Isa Mambetsariev, Giovanny Velasquez, Reza Nadaf-Rahrov, Shaira Therese Dingal, Pauline Kim, Razmig Babikian, Arya Amini, Michelle Afkhami and 1 more

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Translational lung cancer research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. International journal of molecular sciences · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Wai ParkDepartment of Medical Oncology and Therapeutic Research, City of Hope National Medical Center, Duarte, CA, USA.
Jeremy FrickeDepartment of Medical Oncology and Therapeutic Research, City of Hope National Medical Center, Duarte, CA, USA.ORCID https://orcid.org/0000-0003-4684-8114
Isa MambetsarievDepartment of Medical Oncology and Therapeutic Research, City of Hope National Medical Center, Duarte, CA, USA.
Giovanny VelasquezDepartment of Medical Oncology and Therapeutic Research, City of Hope National Medical Center, Duarte, CA, USA.
Reza Nadaf-RahrovDepartment of Medical Oncology and Therapeutic Research, City of Hope National Medical Center, Duarte, CA, USA.
Shaira Therese DingalDepartment of Medical Oncology and Therapeutic Research, City of Hope National Medical Center, Duarte, CA, USA.
Pauline KimDepartment of Pharmacy, City of Hope, Duarte, CA, USA.
Razmig BabikianDepartment of Medical Oncology and Therapeutic Research, City of Hope National Medical Center, Duarte, CA, USA.
Arya AminiDepartment of Radiation Oncology, City of Hope, Duarte, CA, USA.
Michelle AfkhamiDepartment of Pathology, City of Hope, Duarte, CA, USA.
Ravi SalgiaDepartment of Medical Oncology and Therapeutic Research, City of Hope National Medical Center, Duarte, CA, USA.ORCID https://orcid.org/0000-0001-9643-7626

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Tyrosine kinase inhibitors (TKIs) are now the standard of care first-line therapy for epidermal growth factor receptor ( Case Description: Here, we present a case of an NSCLC patient harboring an Conclusions: This case report indicates that identification of germline resistance mutations such as

Indexed as

case reportgermline testingLung adenocarcinomanext-generation sequencing (NGS)targeted therapy

Identifiers

PMID40114953
PMCPMC11921366

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.